TRCT
ADCT icon

Tower Research Capital (TRC)’s ADC Therapeutics ADCT Stock Holding History

Tower Research Capital (TRC)’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$19.6K Buy
18,361
+10,369
+130% +$30.2K ﹤0.01% 3572
2026
Q1 		$30K Buy
7,992
+3,997
+100% +$15.8K ﹤0.01% 3166
2025
Q4 		$14.1K Sell
3,995
-1,614
-29% -$6.55K ﹤0.01% 3368
2025
Q3 		$22.4K Sell
5,609
-7,170
-56% -$22.6K ﹤0.01% 3213
2025
Q2 		$34.2K Buy
12,779
+2,645
+26% +$5.56K ﹤0.01% 3302
2025
Q1 		$14.3K Buy
10,134
+4,537
+81% +$7.71K ﹤0.01% 3304
2024
Q4 		$11.1K Buy
5,597
+951
+20% +$2.49K ﹤0.01% 3746
2024
Q3 		$14.6K Buy
+4,646
New +$14.7K ﹤0.01% 3448
2024
Q1 		– Sell
-14,641
Closed -$24.3K – 5830
2023
Q4 		$24.3K Buy
14,641
+10,521
+255% +$9.71K ﹤0.01% 3536
2023
Q3 		$3.7K Sell
4,120
-1,601
-28% -$2.13K ﹤0.01% 4969
2023
Q2 		$12.3K Buy
5,721
+5,658
+8,981% +$12.7K ﹤0.01% 3887
2023
Q1 		$0 Sell
63
-2,872
-98% -$10.6K ﹤0.01% 5752
2022
Q4 		$11K Sell
2,935
-6,538
-69% -$26.1K ﹤0.01% 3785
2022
Q3 		$46K Buy
9,473
+8,773
+1,253% +$63.5K ﹤0.01% 3227
2022
Q2 		$6K Sell
700
-37
-5% -$350 ﹤0.01% 4887
2022
Q1 		$10K Sell
737
-1,452
-66% -$23K ﹤0.01% 4268
2021
Q4 		$44K Buy
2,189
+2,144
+4,764% +$51.7K ﹤0.01% 2853
2021
Q3 		$1K Buy
+45
New +$1.15K ﹤0.01% 5416
2021
Q2 		– Sell
-82
Closed -$2K – 5425
2021
Q1 		$2K Sell
82
-4,521
-98% -$131K ﹤0.01% 4993
2020
Q4 		$147K Buy
+4,603
New +$151K ﹤0.01% 1998

Other funds holding ADCT

NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $580M AUM 29.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Tower Research Capital (TRC)'s ADCT Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its ADC Therapeutics (ADCT) stake by 130% in Q2 2026, buying an estimated $30.2K and bringing the position to 18,361 shares worth $19.6K. The position accounts for ﹤0.01% of the portfolio, ranked #3572.

Tower Research Capital (TRC) first reported a position in ADCT in Q4 2020 and has held it in 20 quarters since. The position peaked at $147K in Q4 2020. 113 funds tracked by Wall St. Rank hold ADCT as of Q2 2026.

  • Tower Research Capital (TRC) held 18,361 shares of ADC Therapeutics worth $19.6K as of Q2 2026.
  • Tower Research Capital (TRC) bought 10,369 ADC Therapeutics shares in Q2 2026, an estimated $30.2K.
  • ADC Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3572 holding.
  • Tower Research Capital (TRC) first reported a position in ADC Therapeutics in Q4 2020 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s ADC Therapeutics position peaked at $147K in Q4 2020.
  • 113 funds tracked by Wall St. Rank held ADC Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.